I will address two things that clearly show I know what I'm talking about amidst a slew of ignorant responses to my posts.
One point is the fact Algernon and Cannabix collaborated with the FAIMS technology - expenses included. The other point is the FAIMS technology was abandoned by management of Algernon without ever bringing forward a device for shareholders to see like Cannabix's photos. Nor did the ongoing narrative told to shareholders of Algernon by management ever add up to being trustworthy. What I mean by trustworthy is Algernon took the FAIMS device all the way to Version 3 of the handheld process. What Version of device does Cannabix currently have? Version 3 right. That would be the same scenario as if Cannabix up and told shareho;lders they were going to scrap it's breathalyzer and move onto something entirely different.
What folks need to understand is Algernon's mission was not as difficult as Cannabix. The poster who rebuttals every word I post doesn't understand that Algernon was not going to chase after any diseases with it's device. The mission was simply to complete a working device (handheld mass spectrometer) for other scientists/the scientific community to use as a tool in their research. What ultimately abruptly happened was Dr. Yost CUT AND RUN from Algernon and went to Algernon's #1 competitor Owlstone Medical. Yost had left Algernon before the hammer dropped on Algernon shareholders head when they announced they were scrapping the FAIMS altogether. It was an underhanded blow on both fronts! Shareholders got screwed. The exact same tech for Cannabix now is the V3 handheld for Algernon which both companies collaborated on as the following document clearly states. I bring more than name calling and pure B S to my posts. You should clearly be able to tell the difference:
MANAGEMENT’S DISCUSSION AND ANALYSIS
Dated July 27, 2018
Product Development
The Company continues to work to advance the development of a prototype point of care (POC) Faims device. On January 25th the Company announced that in collaboration with Cannabix Technologies (CSE:BLO), the FAIMS V3 prototype was completed. The V3 iteration, is designed to operate both independently with its own self-contained FAIMS detector, or coupled in tandem directly to a triplequadrupole Mass Spectrometer (MS) device. The device also incorporates several technological enhancements, including a modular design for faster iterative development, as well as size reduction into a compact Point-of-Care (POC) design. The collaboration agreement with Cannibix includes sharing research and development costs between both parties in order to more quickly and cost effectively advance a FAIMS POC prototype. It is anticipated that the collaborative agreement will end shortly. Work is continuing to develop a fully functional FAIMS POC prototype that can be used initially to help identify and validate breath-based biomarkers for a variety of diseases and ultimately as a point of care device for screening and or diagnostic tests.
MANAGEMENT’S DISCUSSION AND ANALYSIS
Dated January 28, 2019
Product Development The Company announced on November 5th, 2018 that it has amended its research agreement with the University of Florida’s Analytical Chemistry Department, where Dr. Richard Yost, the Principal Investigator, will work to advance the V3 prototype, or future iterations, through its final stages of prototype development. Dr. Yost is one of the world’s foremost experts on FAIMS technology and has been a scientific advisor with the Company since 2016. Work has begun to transfer the research development program over to the University of Florida’s Analytical Chemistry Department. Before the V3 prototype development phase is successfully completed, the device will need to achieve a number of performance characteristics including device sensitivity, precision and reproducibility in a laboratory setting. Once the prototype work is completed, the device will be ready to be moved into a research use only (RUO) development phase. The goal of this phase will be to engineer and produce field ready devices that will be made available to research scientists worldwide to help advance the discovery and validation of breath-based biomarkers.